Compare Amphastar Pharmaceuticals Inc (AMPH) vs Canadian Natural Resources Ltd. (CNQ) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

CNQ trades at $41.81, down 0.17% on the day, with a bullish technical signal and strong fundamentals. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $0.85 exceeding the $0.74 estimate. Valuation metrics appear attractive with a P/E of 11.8 and EV/EBITDA of 6.54, while profitability remains high with a net income margin of 24.5% and ROE of 25.81%.

The outlook is positive given consistent earnings outperformance, a 75% analyst buy rating, and strong free cash flow supporting shareholder returns. Key risks include oil price volatility and rising debt levels, but the company's operational stability and dividend yield near 4% provide a cushion for investors seeking energy exposure.